Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.64 |
| ▸ | HTR1A | P08908 | 3/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | HTR1D | P28221 | 2/20 | 0.57 |
| ▸ | HTR1B | P28222 | 2/20 | 0.57 |
| ▸ | HTR1F | P30939 | 2/20 | 0.57 |
| ▸ | HTR7 | P34969 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13120194 | 1.00 | HTR6 (0.64) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL4783302 | 0.86 | HTR6 (0.62) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3622212 | 0.84 | HTR6 (0.59) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL13120192 | 0.84 | HTR6 (0.59) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3612612 | 0.84 | HTR6 (0.59) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3622437 | 0.84 | HTR6 (0.63) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3615114 | 0.82 | HTR6 (0.57) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL13120190 | 0.82 | HTR6 (0.57) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL28081142 | 0.79 | HTR6 (0.56) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL7187902 | 0.76 | HTR6 (0.61) | HTR6HTR1ADRD2HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046741-B1 | INDOLES AS 5-HT6 MODULATORS | PROXIMAGEN LTD (GB) | 2012-10-31 | — | — | EP | claimed |
| EP-2046741-B1 | INDOLES AS 5-HT6 MODULATORS | PROXIMAGEN LTD (GB) | 2012-10-31 | — | — | EP | disclosed |
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | disclosed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032968-A1 | New compounds | HTR6, HTR1B, HTR1A | HTR6 1/4885HTR1A 3/4885DRD2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.